| Literature DB >> 36120484 |
Hirofumi Ohashi1, Tomoaki Nawano1, Hiroaki Takashima1, Hirohiko Ando1, Reiji Goto1, Akihiro Suzuki1, Shinichiro Sakurai1, Wataru Suzuki1, Yusuke Nakano1, Hiroaki Sawada1, Masanobu Fujimoto1, Koshiro Sakai2, Yasushi Suzuki1, Katsuhisa Waseda1,3, Tetsuya Amano1.
Abstract
Background: Physiological assessments using fractional flow reserve (FFR) and resting full-cycle ratio (RFR) have been recommended for revascularization decision making. Previous studies have shown a 20% rate of discordance between FFR and RFR. In this context, the correlation between RFR and FFR in patients with renal dysfunction remains unclear. This study examined correlations between RFR and FFR according to renal function. Methods andEntities:
Keywords: Chronic kidney disease; Coronary artery disease; Fractional flow ratio; Resting full-cycle ratio
Year: 2022 PMID: 36120484 PMCID: PMC9437472 DOI: 10.1253/circrep.CR-22-0069
Source DB: PubMed Journal: Circ Rep ISSN: 2434-0790
Figure 1.Study population. DFR, diastolic hyperemia-free ratio; dPR, diastolic pressure ratio; eGFR, estimated glomerular filtration rate; iFR, instantaneous wave-free ratio; NHPR, non-hyperemic pressure ratio.
Baseline Patient Characteristics
| Overall | Group 1 | Group 2 | Group 3 | P value | |
|---|---|---|---|---|---|
| Age (years) | 73.0 [66.5–78.0] | 71.0 [62.0–78.0] | 71.1 [71.0–79.0] | 71.2 [66.5–75.0] | 0.001 |
| Male sex | 201 (76.4) | 118 (74.7) | 71 (80.7) | 12 (70.6) | 0.48 |
| Hypertension | 195 (74.7) | 114 (72.6) | 69 (79.3) | 12 (70.6) | 0.47 |
| Diabetes | 112 (42.6) | 63 (39.9) | 39 (44.3) | 10 (58.8) | 0.30 |
| Dyslipidemia | 186 (71.3) | 114 (72.6) | 65 (74.7) | 7 (41.2) | 0.02 |
| Current smoker | 113 (43.8) | 80 (51.6) | 25 (29.1) | 8 (47.1) | 0.003 |
| Hemodialysis | 14 (5.4) | 0 (0.6) | 0 (0.0) | 14 (82.4) | <0.001 |
| Medication | |||||
| Aspirin | 217 (82.5) | 135 (85.4) | 71 (80.7) | 11 (64.7) | 0.09 |
| Thienopyridine | 69 (26.2) | 38 (24.1) | 27 (30.7) | 4 (23.5) | 0.51 |
| β-blocker | 108 (41.2) | 64 (40.8) | 36 (40.9) | 8 (41.2) | 0.88 |
| Calcium channel blocker | 110 (42.0) | 64 (40.8) | 35 (39.8) | 11 (64.7) | 0.14 |
| Statin | 199 (75.7) | 124 (78.5) | 66 (75.0) | 9 (52.9) | 0.07 |
| Insulin | 10 (3.8) | 6 (3.8) | 2 (2.3) | 2 (11.8) | 0.14 |
| Hb (g/dL) | 13.6 [12.4–14.7] | 14.0 [12.9–15.0] | 13.2 [12.0–14.6] | 11.8 [10.4–13.0] | <0.001 |
| eGFR (mL/min/1.73 m2) | 64.2 [52.0–78.3] | 74.5 [66.8–87.0] | 51.4 [46.9–55.0] | 7.14 [5.8–17.4] | <0.001 |
| Cr (mg/dL) | 0.85 [0.71–1.05] | 0.73 [0.65–0.85] | 1.07 [0.96–1.17] | 6.84 [3.17–8.05] | <0.001 |
Categorical variables are presented as n (%) and continuous variables are presented as the mean±SD or median [interquartile range]. *Variables used for multivariable analyses comparing hazard ratios of symptomatic and asymptomatic patients for the study endpoints. Group 1, estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m2; Group 2, 30 mL/min/1.73 m2≤eGFR<60 mL/min/1.73 m2; Group 3, eGFR <30 mL/min/1.73 m2; Cr, creatinine; Hb, hemoglobin.
Baseline Lesion Characteristics
| Overall | Group 1 | Group 2 | Group 3 | P value | |
|---|---|---|---|---|---|
| Left main trunk | 10 (2.7) | 6 (2.8) | 4 (3.2) | 0 (0.0) | 0.89 |
| Left anterior descending | 193 (52.2) | 115 (52.8) | 64 (54.6) | 14 (50.0) | 0.95 |
| Left circumflex | 75 (20.3) | 43 (19.7) | 25 (20.2) | 7 (25.0) | 0.81 |
| Right coronary artery | 88 (23.8) | 52 (23.9) | 30 (24.2) | 6 (21.4) | 0.95 |
| Reference vessel diameter (mm) | 2.82 [2.39–3.34] | 2.90 [2.35–3.46] | 2.91 [1.29–1.87] | 2.88 [2.20–3.72] | 0.67 |
| Minimum lumen diameter (mm) | 1.73 [1.26–2.26] | 1.59 [1.20–1.94] | 1.29 [1.62–1.87] | 1.71 [1.14–1.91] | 0.85 |
| Diameter stenosis (%) | 46.4±13.6 | 45.5±13.8 | 47.7±12.3 | 47.5±16.9 | 0.32 |
| Lesion length (mm) | 11.69 [8.01–16.40] | 11.7 [7.4–16.0] | 10.7 [8.0–14.8] | 7.82 [6.31–11.5] | 0.10 |
| FFR | 0.82 [0.76–0.88] | 0.83 [0.76–0.89] | 0.81 [0.75–0.88] | 0.82 [0.75–0.89] | 0.39 |
| RFR | 0.91 [0.87–0.96] | 0.92 [0.88–0.96] | 0.91 [0.85–0.95] | 0.88 [0.82–0.91] | 0.009 |
Categorical variables are presented as n (%) and continuous variables are presented as the mean±SD or median [interquartile range]. *Variables used for multivariable analyses comparing hazard ratio of symptomatic and asymptomatic patients for the study endpoints. Group 1, estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m2; Group 2, 30 mL/min/1.73 m2≤eGFR<60 mL/min/1.73 m2; Group 3, eGFR <30 mL/min/1.73 m2; FFR, fractional flow reserve; RFR, resting full-cycle ratio.
Figure 2.Relationship between resting full-cycle ratio (RFR) and fractional flow reserve (FFR) in (A,B) Group 1 (estimated glomerular filtration rate [eGFR] ≥60 mL/min/1.73 m2), (C,D) Group 2 (30 mL/min/1.73 m2≤eGFR<60 mL/min/1.73 m2), and (E,F) Group 3 (eGFR <30 mL/min/1.73 m2). (A,C,E) Correlation plots between RFR and FFR. (B,D,F) Receiver operating characteristic (ROC) curves of RFR values for an FFR cut-off value of 0.80. AUC, area under the curve; CI, confidence interval.
Figure 3.Rates of discordance between resting full-cycle ratio (RFR) and fractional flow reserve (FFR) according to (A) renal function after Bonferroni correction and (B) chronic kidney disease (CKD) stage. The CKD stages were as follows: G1, estimated glomerular filtration rate (eGFR) ≥90 mL/min/1.73 m2; G2, 60 mL/min/1.73 m2≤eGFR<89 mL/min/1.73 m2; G3a, 45 mL/min/1.73 m2≤eGFR<59 mL/min/1.73 m2; G3b, 30 mL/min/1.73 m2≤eGFR<44 mL/min/1.73 m2; G4, 15 mL/min/1.73 m2≤eGFR<29 mL/min/1.73 m2; G5, eGFR <15 mL/min/1.73 m2.